NHLI yields 2000000.00% · ABBV yields 3.06%● Live data
📍 NHLI pulled ahead of the other in Year 1
Combined, NHLI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NHLI + ABBV for your $10,000?
Nouveau Holdings, Ltd., a development stage company, operates as a green mining equipment technology company. The company offers mining equipment and drilling technologies for the exploration, extraction, and environmentally conscious mining of gold, silver, and platinum. It also holds patent rights for developing laser guidance system for diamond wire stone cutting apparatus; safe system used in mineshaft illumination; continuous refractory ore bioprocessing apparatus that monitors the digestion of metal ore for silver, gold, and platinum using bacteria in a controlled agitation tank; and biomining ore processing bioreactor apparatus. In addition, Spectrum Acquisition Holdings, Inc. is developing a patent pending mixing, milling, and aeration apparatus for digesting metal ore with bacteria. The company was formerly known as Spectrum Acquisition Holdings, Inc. and changed its name to Nouveau Holdings, Ltd. in April 2013. Nouveau Holdings, Ltd. was incorporated in 1987 and is based in Austin, Texas.
Full NHLI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.